S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
S&P 500   3,168.57 (+0.86%)
DOW   28,132.05 (+0.79%)
QQQ   206.51 (+0.75%)
AAPL   271.46 (+0.25%)
FB   196.75 (-2.72%)
MSFT   153.24 (+1.02%)
GOOGL   1,348.49 (+0.32%)
AMZN   1,760.33 (+0.66%)
CGC   21.13 (+4.35%)
NVDA   224.32 (+3.21%)
MU   50.97 (+3.47%)
BABA   204.50 (-0.07%)
GE   11.44 (+4.28%)
TSLA   359.68 (+1.98%)
T   38.35 (+0.47%)
AMD   42.59 (+7.90%)
ACB   2.60 (+6.12%)
F   9.32 (+2.31%)
PRI   136.50 (+0.78%)
NFLX   298.50 (-0.14%)
BAC   34.68 (+3.09%)
GILD   67.63 (-0.22%)
DIS   147.76 (+0.12%)
Log in

NASDAQ:VCEL - Vericel Stock Price, Forecast & News

$17.77
-0.07 (-0.39 %)
(As of 12/12/2019 04:00 PM ET)
Today's Range
$17.34
Now: $17.77
$17.93
50-Day Range
$15.77
MA: $17.94
$19.09
52-Week Range
$13.40
Now: $17.77
$21.00
Volume506,857 shs
Average Volume546,103 shs
Market Capitalization$794.23 million
P/E RatioN/A
Dividend YieldN/A
Beta2.72
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VCEL
CUSIPN/A
Phone800-556-0311

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$90.86 million
Book Value$2.36 per share

Profitability

Net Income$-8,140,000.00

Miscellaneous

Employees216
Market Cap$794.23 million
Next Earnings Date2/25/2020 (Estimated)
OptionableOptionable

Receive VCEL News and Ratings via Email

Sign-up to receive the latest news and ratings for VCEL and its competitors with MarketBeat's FREE daily newsletter.


Vericel (NASDAQ:VCEL) Frequently Asked Questions

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

How were Vericel's earnings last quarter?

Vericel Corp (NASDAQ:VCEL) posted its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.02) by $0.09. The biotechnology company earned $30.50 million during the quarter, compared to analyst estimates of $26.84 million. Vericel had a negative net margin of 12.68% and a positive return on equity of 3.66%. The company's quarterly revenue was up 35.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.02) earnings per share. View Vericel's Earnings History.

When is Vericel's next earnings date?

Vericel is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Vericel.

What price target have analysts set for VCEL?

4 brokerages have issued 12-month target prices for Vericel's stock. Their forecasts range from $17.92 to $32.00. On average, they anticipate Vericel's share price to reach $23.23 in the next twelve months. This suggests a possible upside of 30.7% from the stock's current price. View Analyst Price Targets for Vericel.

What is the consensus analysts' recommendation for Vericel?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vericel.

Has Vericel been receiving favorable news coverage?

News headlines about VCEL stock have trended extremely negative on Thursday, InfoTrie reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vericel earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the company's share price in the immediate future. View News Stories for Vericel.

Who are some of Vericel's key competitors?

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Momo (MOMO), Novavax (NVAX), Dynavax Technologies (DVAX), NVIDIA (NVDA), Amarin (AMRN), Verastem (VSTM), Progenics Pharmaceuticals (PGNX) and TG Therapeutics (TGTX).

Who are Vericel's key executives?

Vericel's management team includes the folowing people:
  • Mr. Dominick C. Colangelo Esq., CEO, Pres & Director (Age 55)
  • Mr. Gerard J. Michel, CFO & VP of Corp. Devel. (Age 56)
  • Mr. Daniel R. Orlando, Chief Operating Officer (Age 54)
  • Ms. Jacquelyn Fahey Sandell, VP, Gen. Counsel & Corp. Sec.
  • Ms. Heidi Hassen, Sr. Director of HR

Who are Vericel's major shareholders?

Vericel's stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (4.25%), Emerald Advisers LLC (1.71%), GW&K Investment Management LLC (1.62%), Russell Investments Group Ltd. (1.04%), Calamos Advisors LLC (0.92%) and Perkins Capital Management Inc. (0.90%). Company insiders that own Vericel stock include Alan L Rubino, Daniel Orlando, Dominick Colangelo, Gerard J Michel, Michael Halpin, Paul K Wotton and Steven C Gilman. View Institutional Ownership Trends for Vericel.

Which institutional investors are selling Vericel stock?

VCEL stock was sold by a variety of institutional investors in the last quarter, including SG Capital Management LLC, State Street Corp, Squarepoint Ops LLC, Perkins Capital Management Inc., Barclays PLC, Emerald Advisers LLC, Essex Investment Management Co. LLC and Alps Advisors Inc.. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Gerard J Michel, Michael Halpin, Paul K Wotton and Steven C Gilman. View Insider Buying and Selling for Vericel.

Which institutional investors are buying Vericel stock?

VCEL stock was purchased by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, SG Americas Securities LLC, California Public Employees Retirement System, Granahan Investment Management Inc. MA, Insight Wealth Strategies LLC, BBVA USA Bancshares Inc., Boston Advisors LLC and Conestoga Capital Advisors LLC. View Insider Buying and Selling for Vericel.

How do I buy shares of Vericel?

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $17.77.

How big of a company is Vericel?

Vericel has a market capitalization of $794.23 million and generates $90.86 million in revenue each year. The biotechnology company earns $-8,140,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Vericel employs 216 workers across the globe.View Additional Information About Vericel.

What is Vericel's official website?

The official website for Vericel is http://www.vcel.com/.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 800-556-0311 or via email at [email protected]


MarketBeat Community Rating for Vericel (NASDAQ VCEL)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  274 (Vote Outperform)
Underperform Votes:  282 (Vote Underperform)
Total Votes:  556
MarketBeat's community ratings are surveys of what our community members think about Vericel and other stocks. Vote "Outperform" if you believe VCEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/12/2019 by MarketBeat.com Staff

Featured Article: Backdoor Roth IRA

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel